As of November 6, 2026, Humacyte, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 28, 2026, naming 1 appointment. The latest filing names Scott Coward, appointed (Form 8-K, September 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Humacyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Humacyte, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-28. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Humacyte, Inc. files it.
Also on the record for Humacyte, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 18, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care Holdings, Inc. | 4.9% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.5% of the class | 5%+ stakes | Source |
| July 13, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care Holdings, Inc. | 6.8% of the class | 5%+ stakes | Source |
| June 22, 2026 | Stake report, Schedule 13G, by Davidson Kempner Capital Management LP | 4.74% of the class | 5%+ stakes | Source |
| June 15, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care Holdings, Inc. | 6.8% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care Holdings, Inc. | 8.4% of the class | 5%+ stakes | Source |
| March 24, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care Holdings, Inc. | 8.4% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13D/A, by Fresenius Medical Care AG | 9.5% of the class | 5%+ stakes | Source |
| October 16, 2025 | Stake report, Schedule 13D/A, by Fresenius Medical Care AG | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Humacyte, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Humacyte, Inc. and the records around it.
Humacyte, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- M.H. Davidson & Co. also filed stake reports on 17 other companies: Greenland Mines Ltd (Sep 2026), Qtrex Quantum Ltd. (Aug 2026), AIB Data Centers Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Humacyte, Inc.
Get an email when Humacyte, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Humacyte, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Humacyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Humacyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-28 | In | 8-K, 2026-09-28 |
New leaders reset buying decisions — get the Full Report on Humacyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Humacyte, Inc., with the record behind each one.
Find candidates like senior executive at Humacyte, Inc.Every change, in the filing's words
Appointed: Scott Coward
On September 22, 2026, the Board of Directors (the "Board") of Humacyte, Inc. (the "Company"), appointed Scott Coward and Paul Kuznik to the Board.
- Mr. Coward will serve as a Class I director with a term expiring in 2028, or until his earlier death, resignation, retirement, disqualification or removal.
- Mr. Kuznik will serve as a Class II director with a term expiring in 2029, or until his earlier death, resignation, retirement, disqualification or removal.
- Mr. Coward has been an attorney at K&L Gates since July 2026, previously serving as the managing partner of the Raleigh office.
- Prior to that, he served as Executive Vice President, Chief Legal Officer, Chief Administrative Officer and Secretary of Exact Sciences Corporation from January 2015 to December 2022.
- Mr. Coward led the integration of Genomic Health Corporation following its acquisition by Exact Sciences.
- He served on the Exact Sciences board of directors from December 2022 to March 2026.
- Mr. Coward brings significant experience in public company board service and corporate governance, executive leadership within publicly traded life sciences companies, mergers and acquisitions and post-acquisition integration, executive compensation, compliance and legal affairs, organizational leadership during periods of substantial growth and change, and has partnered with executive management teams and boards through transformational corporate events.
- Mr. Coward received his J.D. from Columbia Law School and his B.S. from the University of North Carolina at Chapel Hill.
Tools for this story
Each opens in a new tab, filled in for Humacyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.